Ventripoint Diagnostics Ltd. develops diagnostic tools for monitoring heart disease. While the company boasts a strong gross margin of 100%, it faces significant concerns with an EBITDA margin of -1481.5% and a net margin of -1778.6%, indicating severe profitability issues. Additionally, a current ratio of 0.08 suggests liquidity challenges. The high gross margin juxtaposed with low valuation and negative margins raises questions about operational efficiency and financial sustainability. Overall, VPT.V presents both potential in its niche market and significant financial hurdles to overcome.
Loading financial metrics...
Company has $55K in cash but burned $389K last quarter. At this burn rate, only 0.1 quarters of runway remain without additional financing.
Company posted a loss of $-3.2M over the last year, representing 1778.6% of revenue.
Debt of $2.6M is 47.1x the company's cash position of $55K.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.6M over the last year.
Exceptional revenue growth of 89.1% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 3156.0pp, demonstrating strong operational leverage.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical Devices companies of a similar size
Based on 2025-FY (December 31, 2025)